Logo image of IOVA

IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Fundamental Analysis

NASDAQ:IOVA - Nasdaq - US4622601007 - Common Stock - Currency: USD

3.59  +0.03 (+0.84%)

Premarket: 3.63 +0.04 (+1.11%)

Fundamental Rating

3

Taking everything into account, IOVA scores 3 out of 10 in our fundamental rating. IOVA was compared to 566 industry peers in the Biotechnology industry. While IOVA seems to be doing ok healthwise, there are quite some concerns on its profitability. IOVA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IOVA has reported negative net income.
IOVA had a negative operating cash flow in the past year.
In the past 5 years IOVA always reported negative net income.
IOVA had a negative operating cash flow in each of the past 5 years.
IOVA Yearly Net Income VS EBIT VS OCF VS FCFIOVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

IOVA has a Return On Assets (-40.88%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -52.39%, IOVA is in the better half of the industry, outperforming 63.43% of the companies in the same industry.
Industry RankSector Rank
ROA -40.88%
ROE -52.39%
ROIC N/A
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
IOVA Yearly ROA, ROE, ROICIOVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Gross Margin of IOVA (24.43%) is better than 72.61% of its industry peers.
The Profit Margin and Operating Margin are not available for IOVA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 24.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IOVA Yearly Profit, Operating, Gross MarginsIOVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

4

2. Health

2.1 Basic Checks

IOVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IOVA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IOVA has more shares outstanding
Compared to 1 year ago, IOVA has an improved debt to assets ratio.
IOVA Yearly Shares OutstandingIOVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
IOVA Yearly Total Debt VS Total AssetsIOVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -0.92, we must say that IOVA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.92, IOVA is in the better half of the industry, outperforming 60.42% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that IOVA is not too dependend on debt financing.
IOVA has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.92
ROIC/WACCN/A
WACC9.91%
IOVA Yearly LT Debt VS Equity VS FCFIOVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 3.74 indicates that IOVA has no problem at all paying its short term obligations.
IOVA has a Current ratio of 3.74. This is comparable to the rest of the industry: IOVA outperforms 44.88% of its industry peers.
A Quick Ratio of 3.31 indicates that IOVA has no problem at all paying its short term obligations.
IOVA's Quick ratio of 3.31 is in line compared to the rest of the industry. IOVA outperforms 41.17% of its industry peers.
Industry RankSector Rank
Current Ratio 3.74
Quick Ratio 3.31
IOVA Yearly Current Assets VS Current LiabilitesIOVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

IOVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.85%, which is quite impressive.
Looking at the last year, IOVA shows a very strong growth in Revenue. The Revenue has grown by 13664.26%.
EPS 1Y (TTM)30.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.22%
Revenue 1Y (TTM)13664.26%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%15189.21%

3.2 Future

The Earnings Per Share is expected to grow by 22.21% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 55.31% on average over the next years. This is a very strong growth
EPS Next Y38.43%
EPS Next 2Y32.27%
EPS Next 3Y31.41%
EPS Next 5Y22.21%
Revenue Next Year178.96%
Revenue Next 2Y112.65%
Revenue Next 3Y83.05%
Revenue Next 5Y55.31%

3.3 Evolution

IOVA Yearly Revenue VS EstimatesIOVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
IOVA Yearly EPS VS EstimatesIOVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IOVA. In the last year negative earnings were reported.
Also next year IOVA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IOVA Price Earnings VS Forward Price EarningsIOVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IOVA Per share dataIOVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as IOVA's earnings are expected to grow with 31.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.27%
EPS Next 3Y31.41%

More info and screens

0

5. Dividend

5.1 Amount

IOVA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IOVANCE BIOTHERAPEUTICS INC

NASDAQ:IOVA (4/30/2025, 8:14:22 PM)

Premarket: 3.63 +0.04 (+1.11%)

3.59

+0.03 (+0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)05-13 2025-05-13/amc
Inst Owners82.91%
Inst Owner Change-0.68%
Ins Owners0.26%
Ins Owner Change18.13%
Market Cap1.18B
Analysts83
Price Target19.57 (445.13%)
Short Float %25.56%
Short Ratio6.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.42%
Min EPS beat(2)4.58%
Max EPS beat(2)8.26%
EPS beat(4)4
Avg EPS beat(4)5.26%
Min EPS beat(4)2.54%
Max EPS beat(4)8.26%
EPS beat(8)7
Avg EPS beat(8)11.99%
EPS beat(12)10
Avg EPS beat(12)9.11%
EPS beat(16)10
Avg EPS beat(16)5.77%
Revenue beat(2)1
Avg Revenue beat(2)3.24%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)6.69%
Revenue beat(4)2
Avg Revenue beat(4)-8.93%
Min Revenue beat(4)-66.23%
Max Revenue beat(4)24.03%
Revenue beat(8)2
Avg Revenue beat(8)-48.03%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.44%
PT rev (3m)-19.3%
EPS NQ rev (1m)0.37%
EPS NQ rev (3m)-4.07%
EPS NY rev (1m)2.1%
EPS NY rev (3m)0.31%
Revenue NQ rev (1m)-1.97%
Revenue NQ rev (3m)0.37%
Revenue NY rev (1m)0.6%
Revenue NY rev (3m)3.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.17
P/FCF N/A
P/OCF N/A
P/B 1.66
P/tB 2.75
EV/EBITDA N/A
EPS(TTM)-1.3
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-1.11
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0.5
BVpS2.17
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.88%
ROE -52.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 24.43%
FCFM N/A
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.37%
Cap/Sales 6.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.74
Quick Ratio 3.31
Altman-Z -0.92
F-Score6
WACC9.91%
ROIC/WACCN/A
Cap/Depr(3y)118.96%
Cap/Depr(5y)1133.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.22%
EPS Next Y38.43%
EPS Next 2Y32.27%
EPS Next 3Y31.41%
EPS Next 5Y22.21%
Revenue 1Y (TTM)13664.26%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%15189.21%
Revenue Next Year178.96%
Revenue Next 2Y112.65%
Revenue Next 3Y83.05%
Revenue Next 5Y55.31%
EBIT growth 1Y15.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.78%
EBIT Next 3Y27.6%
EBIT Next 5YN/A
FCF growth 1Y5.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.44%
OCF growth 3YN/A
OCF growth 5YN/A